Realistic expectation: Users running microneedling plus GHK-Cu often see at week 8 what topical-only users see at week 12
The FDA's decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months
In a study published in 2022 called the STEP-8 clinical trial, researchers compared the weight loss effect of Wegovy vs
Let's break down how these two components complement each other in a comprehensive wellness plan
Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (follistatin-344), GHK-Cu (glycyl-l-histidyl-l-lysine copper), ipamorelin, MOTS-C (mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (elamipretide), tesamorelin (Egrifta), T4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment)